Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
暂无分享,去创建一个
J. Kasprzak | R. Becker | R. Mehran | T. Povsic | S. Zelenkofske | Mauricio G. Cohen | C. Buller | J. Cornel | J. Alexander | G. Montalescot | I. Sarembock | J. Vavalle | P. Fail | Laura H. Aberle
[1] J. Ware,et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. , 2007, JAMA.
[2] G. Levine,et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. , 2003, Journal of the American College of Cardiology.
[3] G. Parodi,et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). , 2010, The American journal of cardiology.
[4] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[5] J. Ware,et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial , 2007, The Lancet.
[6] J. Kasprzak,et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. , 2013, European heart journal.
[7] Salim Yusuf,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.
[8] J. Oliver,et al. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. , 1995, Blood.
[9] E. Antman,et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial , 2009, The Lancet.
[10] D. Monroe,et al. Transmission of a procoagulant signal from tissue factor‐bearing cells to platelets , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[11] R. Becker,et al. The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study , 2014, Journal of Thrombosis and Thrombolysis.
[12] J. Ware,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.
[13] R. Becker,et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. , 2011, European heart journal.
[14] J. Kasprzak,et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. , 2011, American heart journal.
[15] R. Becker,et al. A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.
[16] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[17] R. Becker,et al. Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design , 2011, Journal of Thrombosis and Thrombolysis.
[18] I. Porto,et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. , 2009, QJM : monthly journal of the Association of Physicians.
[19] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[20] H. White,et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.
[21] R. Becker,et al. First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention , 2010, Circulation.
[22] S. Steinhubl,et al. First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.